{"slideshow_credits": null, "snippet": "The Generic Pharmaceutical Association responds to an editorial.", "abstract": null, "section_name": "Opinion", "print_page": "", "document_type": "article", "byline": [], "web_url": "http://www.nytimes.com/2013/05/10/opinion/generic-biotech-drugs.html", "lead_paragraph": "The Generic Pharmaceutical Association responds to an editorial.", "headline": {"main": "Generic Biotech Drugs", "print_headline": "Generic Biotech Drugs", "content_kicker": "Letter", "kicker": "Letter"}, "_id": "518c4f2840e9ec6175443186", "word_count": "169", "multimedia": [], "pub_date": "2013-05-10T00:00:00Z", "source": "The New York Times", "news_desk": "Letters", "keywords": [{"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "N", "rank": "1"}, {"value": "State Legislatures", "name": "subject", "is_major": "N", "rank": "2"}, {"value": "Generic Brands and Products", "name": "subject", "is_major": "N", "rank": "3"}], "blog": [], "subsection_name": null, "type_of_material": "Letter"}